 Novo Nordisk’s GLP-1 heavyweight Wegovy could soon reach many more patients in Britain after the United Kingdom’s cost-effectiveness gatekeeper cleared the drug in a use beyond obesity. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
